| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Cai,Sen-Tian | Chairman | 0.00% | |
| Zhang,Shi-Zhong | Director | 59.22% | MEDIGEN BIOTECHNOLOGY CORP. |
| Jiang,Ya-Ling | Director | 59.22% | MEDIGEN BIOTECHNOLOGY CORP. |
| Wang,You-Zheng | Director | 1.46% | |
| Liu,Xiao-Jun | Independent Director | 0.00% | |
| Wang,Yao-Xian | Independent Director | 0.00% | |
| Lin,Shi-Xun | Independent Director | 0.00% |
Change Person in Charge to Cai,Sen-Tian
2023/06/21
Change Capital to 500,000,000
2021/05/04
Change Capital to 181,670,000
2021/01/22
Change Capital to 500,000,000
2017/06/28
Change Person in Charge to Zhang,Shi-Zhong
2014/02/24
Change Capital to 350,000,000
2012/03/05
Change Person in Charge to Zhang,Tian-Ci
2012/03/05
Change Capital to 265,000,000
2011/07/20
Change Capital to 240,000,000
2011/04/07
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 695,077 | 709,074 | 606,517 |
| Operating cost | 379,237 | 361,476 | 342,069 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 315,840 | 347,598 | 264,448 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 315,840 | 347,598 | 264,448 |
| Operating expenses | 156,585 | 151,497 | 128,585 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 159,255 | 196,101 | 135,863 |
| Non-operating income and expenses | 4,925 | 2,717 | 5,535 |
| Net profit (loss) before tax | 164,180 | 198,818 | 141,398 |
| Income tax expense (benefits) | 32,587 | 40,063 | 30,137 |
| Net profit (loss) of ongoing business for the current period | 131,593 | 158,755 | 111,261 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 131,593 | 158,755 | 111,261 |
| Other comprehensive profit (loss), net | 1,440 | -442 | -1,204 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 133,033 | 158,313 | 110,057 |
| Net profit (loss) attributable to owners of parent company | 131,593 | 158,755 | 111,261 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 133,033 | 158,313 | 110,057 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 7 | 8 | 6 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 148,086 | 215,448 | 124,884 |
| Net cash inflows (outflows) from investing activities | -18,262 | -19,882 | -8,622 |
| Net cash inflow (outflow) from financing activities | -129,411 | -99,098 | -76,394 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | 413 | 96,468 | 39,868 |
| Beginning balance of cash and cash equivalents | 299,139 | 202,671 | 162,803 |
| Ending balance of cash and cash equivalents | 299,552 | 299,139 | 202,671 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 624,023 | 599,822 | 498,432 |
| Non-current asset | 188,650 | 201,954 | 202,999 |
| Total asset | 812,673 | 801,776 | 701,431 |
| Current liability | 310,702 | 298,690 | 263,457 |
| Non-current liability | 62,589 | 75,185 | 76,301 |
| Total liability | 373,291 | 373,875 | 339,758 |
| share capital | 184,170 | 184,170 | 184,170 |
| Equity - secruity token | - | - | - |
| capital reserve | 17,401 | 17,401 | 17,401 |
| retained earning | 237,811 | 226,330 | 160,102 |
| Other equity | - | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 439,382 | 427,901 | 361,673 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 439,382 | 427,901 | 361,673 |
| Share capital awaiting retirement (unit: share) | - | - | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 23 | 23 | 19 |
